To evaluate how prior corticosteroid treatment affects canine lymphocyte responsiveness to PD-1/PD-L1 axis blockade or rhIL-12, we assessed the ex vivo responses of cancer patient-derived PBMCs (Supplementary Figure 1). This evidence concerns the gene SPRR2A and cancer.